Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

作者
Richard D. Carvajal,Gary K. Schwartz,Helen Mann,Ian Smith,Paul Nathan
出处
期刊:BMC Cancer [BioMed Central]
卷期号:15 (1): 467-467 被引量:56
标识
DOI:10.1186/s12885-015-1470-z
摘要

BACKGROUND: Uveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway activation. Treatment with selumetinib (AZD6244, ARRY-142886), a MEK1/2 inhibitor, results in antitumour effects in uveal melanoma pre-clinical models. A randomised phase II trial demonstrated improved progression-free survival (PFS) and response rate (RR) with selumetinib monotherapy versus chemotherapy with temozolomide or dacarbazine in patients with metastatic uveal melanoma. Pre-clinically, selumetinib in combination with alkylating agents enhanced antitumour activity compared with chemotherapy alone. We hypothesise that selumetinib in combination with dacarbazine will result in improved clinical outcomes in patients with metastatic uveal melanoma versus dacarbazine alone. METHODS/DESIGN: SUMIT is a randomised, international, double-blind, placebo-controlled, phase III study assessing the efficacy and safety of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma who have not received prior systemic therapy. Primary endpoint is PFS. Secondary endpoints include objective RR, duration of response, change in tumour size at Week 6, overall survival, safety and tolerability. Exploratory endpoints include efficacy in tumours with GNAQ or GNA11 mutations. Eligible patients must have: ≥1 lesion that can be accurately measured at baseline, and is suitable for accurate repeated measurements; ECOG performance status 0-1; life expectancy>12 weeks. Mutation status for GNAQ/GNA11 will be assessed retrospectively. An estimated 128 patients from approximately 50 sites globally will be randomised (3:1) to selumetinib 75 mg twice daily or placebo in combination with dacarbazine 1000 mg/m(2) on Day 1 of every 21-day cycle until objective disease progression, intolerable toxicity or occurrence of another discontinuation criterion. Randomisation will be stratified by the presence/absence of liver metastases. Tumours will be evaluated by RECIST v1.1 every 6 weeks. All patients have the option of receiving selumetinib with or without dacarbazine at disease progression. Study enrolment began in April 2014 and is expected to complete in early 2015. DISCUSSION: Treatment of patients with metastatic uveal melanoma represents an area of high unmet medical need. This study evaluating selumetinib in combination with dacarbazine was designed with input from the US FDA, and is the first potential registration trial to be conducted in patients with metastatic uveal melanoma. TRIAL REGISTRATION: Clinicaltrials.gov (Date of registration, October 10, 2013) REGISTRATION NUMBER: NCT01974752 Trial abbreviation: SUMIT.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lucaslucas完成签到 ,获得积分10
刚刚
delusionY完成签到 ,获得积分10
1秒前
Saber完成签到,获得积分10
1秒前
完美世界的应助被alandan采纳,获得10
1秒前
Cecilia完成签到,获得积分10
2秒前
尘有心完成签到 ,获得积分10
2秒前
爆米花的应助被liangchao采纳,获得50
2秒前
科研通AI6.2的应助被liangchao采纳,获得50
2秒前
科研通AI6.2的应助被liangchao采纳,获得50
2秒前
光亮向真发布了新的文献求助10
3秒前
6秒前
6秒前
6秒前
7秒前
姜糊完成签到 ,获得积分10
7秒前
yishu完成签到,获得积分20
8秒前
缺粥发布了新的文献求助10
9秒前
北冰洋的繇鱼完成签到,获得积分10
9秒前
yulihh完成签到,获得积分10
9秒前
9秒前
啊啊啊啊啊啊啊完成签到,获得积分10
10秒前
杨子墨发布了新的文献求助10
10秒前
Hh完成签到,获得积分10
11秒前
ffffwj2024完成签到,获得积分10
11秒前
研友_X89o6n完成签到,获得积分10
11秒前
小王发布了新的文献求助10
11秒前
生动的乐曲完成签到,获得积分10
11秒前
12秒前
生动的访琴完成签到,获得积分10
12秒前
r12r1完成签到,获得积分10
13秒前
姜姜完成签到,获得积分10
13秒前
throb发布了新的文献求助10
13秒前
零零1完成签到 ,获得积分10
14秒前
碎觉觉发布了新的文献求助10
15秒前
16秒前
16秒前
16秒前
Nuyoah完成签到 ,获得积分10
17秒前
转复窦律完成签到,获得积分10
17秒前
粗犷的翎完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054